GlassScriptPhysician profile
Robert A Lowenthal
NPI 1871509323
$30,649.02
in general payments reported to CMS, 2019-2025
9 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $61.12 · 2021: $215 · 2022: $100 · 2023: $759 · 2024: $604 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,619.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,619.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultradent Products INC | $28,520.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $616.39 | 2021-2025 | Eylea Hd, Eylea |
| Genentech USA, INC. | $594.19 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $329.23 | 2022-2023 | Syfovre |
| Astellas Pharma US INC | $272.47 | 2024-2025 | Izervay |
| Ocular Therapeutix, INC. | $140.01 | 2024 | Dextenza |
| Regeneron Pharmaceuticals, INC. | $87.78 | 2023 | Eylea Hd |
| Abbvie INC. | $72.52 | 2024 | |
| Thea Pharma INC. | $16.43 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lowenthal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.